Orgenesis and CureCell Create Joint Venture for Contract Development and Manufacturing of Cell Therapy Products in South Korea

GERMANTOWN, MD--(Marketwired - Jun 1, 2016) -  Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, along with MaSTherCell SA, its wholly-owned, vertically integrated CDMO, specializing in cell therapy development for advanced medicinal products (the "Company"), today announced that it has entered into a joint venture agreement with South Korean-based CureCell Co. Ltd. ("CureCell"). The joint venture will enable the two progressive organizations to collaborate in the contract development and manufacturing of cell therapy products in South Korea.

Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs). CureCell is a Korean based company that is focused on developing innovative regenerative therapies for both the Korean and international markets.

"South Korea is one of the top nations in the world for supporting cell therapy and regenerative medicine and CureCell is on the cutting edge of innovation and advancement in this industry," said Vered Caplan, CEO of Orgenesis. "We look forward to collaborating closely with CureCell to drive advanced contract manufacturing initiatives in an effort to deliver new cell therapy products in South Korea and around the world."

The intellectual property included in the license from the Tel Hashomer Hospital in Israel to Orgenesis Ltd., which is a subsidiary of Orgenesis Inc., is not part of this joint venture.

About CureCell Co. Ltd.

CureCell is a Korean based company who is focused on developing innovative regenerative therapies for both the Korean and international markets. CureCell's management has identified several cell-therapy technologies that are developed in Korea in parallel to potential developments in the US and Europe. CureCell will focus on developing foreign technologies in Korea and Asia and in expanding international markets for Korean technologies. CureCell collaborates closely with leading medical and academic facilities aiming to become a market leader in the field of therapeutic development in Korea.